eli lilly is one of our favorites in 2022: bank of america pharma analyst
Published 2 years ago • 3.7K plays • Length 2:00Download video MP4
Download video MP3
Similar videos
-
3:00
bank of america names eli lilly a top pick
-
4:19
eli lilly is a 'great destination for investors', says deutsche bank's james shin after upgrade
-
6:43
eli lilly ceo on weight loss drugs outlook: our top priority is making more product
-
4:19
expect eli lilly's momentum to continue, says bank of america's geoff meacham
-
4:22
fda approves a new alzheimer's drug from eli lilly
-
5:33
eli lilly ceo david ricks on 3-year obesity drug study: this is a profound result
-
4:09
excitement grows around eli lilly's glp-1 drugs in q2 earnings
-
6:00
eli lilly's zepbound may be best-in-breed for weight loss drugs, says dr. kavita patel
-
3:17
bofa's geoff meacham on eli lilly on q4 results: the story has changed to diabetes and obesity
-
7:33
why eli lilly is a top glp-1 stock: roundhill ceo
-
2:59
3-stock lunch: nvidia, eli lilly, paramount
-
3:31
call of the day: eli lilly
-
3:00
eli lilly is becoming the 'goat' of obesity, says bmo's evan seigerman
-
1:38
chart of the day: eli lilly
-
1:49
here's a breakdown of big pharma earnings from merck, pfizer, eli lilly
-
0:55
eli lilly ceo on compounded versions of weight loss drugs
-
3:58
eli lilly hits record high: here's what investors need to know
-
2:40
eli lilly slashes prices of low doses of weight loss drug by scrapping auto-injector
-
4:23
two bullish calls on eli lilly
-
5:22
eii lilly's weight-loss drug is 'much better' than others on the market, says wells fargo's bansal
-
3:43
eli lilly's valuation is justified when you look at the growth profile, says ubs' bristow
-
3:14
eli lilly ceo on raising $1b for antibiotic research: goal is to have two to four new antibiotics